304 related articles for article (PubMed ID: 23552692)
1. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions.
Jung HM; Patel RS; Phillips BL; Wang H; Cohen DM; Reinhold WC; Chang LJ; Yang LJ; Chan EK
Mol Biol Cell; 2013 Jun; 24(11):1638-48, S1-7. PubMed ID: 23552692
[TBL] [Abstract][Full Text] [Related]
2. CIP2A expression and localization in oral carcinoma and dysplasia.
Katz J; Jakymiw A; Ducksworth MK; Stewart CM; Bhattacharyya I; Cha S; Chan EK
Cancer Biol Ther; 2010 Oct; 10(7):694-9. PubMed ID: 21068540
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
[TBL] [Abstract][Full Text] [Related]
4. miR-548b-3p Regulates Proliferation, Apoptosis, and Mitochondrial Function by Targeting CIP2A in Hepatocellular Carcinoma.
Lin L; Wang Y
Biomed Res Int; 2018; 2018():7385426. PubMed ID: 30671469
[TBL] [Abstract][Full Text] [Related]
5. Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway.
Wu J; Ding M; Mao N; Wu Y; Wang C; Yuan J; Miao X; Li J; Shi Z
J Pharmacol Sci; 2017 May; 134(1):22-28. PubMed ID: 28522217
[TBL] [Abstract][Full Text] [Related]
6. CIP2A inhibits PP2A in human malignancies.
Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
[TBL] [Abstract][Full Text] [Related]
7. Low expression of miR-let-7a promotes cell growth and invasion through the regulation of c-Myc in oral squamous cell carcinoma.
Luo C; Zhang J; Zhang Y; Zhang X; Chen Y; Fan W
Cell Cycle; 2020 Aug; 19(15):1983-1993. PubMed ID: 32594835
[TBL] [Abstract][Full Text] [Related]
8. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.
Wiegering A; Pfann C; Uthe FW; Otto C; Rycak L; Mäder U; Gasser M; Waaga-Gasser AM; Eilers M; Germer CT
PLoS One; 2013; 8(10):e75292. PubMed ID: 24098375
[TBL] [Abstract][Full Text] [Related]
9. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
[TBL] [Abstract][Full Text] [Related]
10. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
11. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
Khanna A; Böckelman C; Hemmes A; Junttila MR; Wiksten JP; Lundin M; Junnila S; Murphy DJ; Evan GI; Haglund C; Westermarck J; Ristimäki A
J Natl Cancer Inst; 2009 Jun; 101(11):793-805. PubMed ID: 19470954
[TBL] [Abstract][Full Text] [Related]
12. CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression.
Wu Y; Gu TT; Zheng PS
Cancer Lett; 2015 Jan; 356(2 Pt B):646-55. PubMed ID: 25458953
[TBL] [Abstract][Full Text] [Related]
13. CIP2A regulates MYC translation (via its 5'UTR) in colorectal cancer.
Denk S; Schmidt S; Schurr Y; Schwarz G; Schote F; Diefenbacher M; Armendariz C; Dejure F; Eilers M; Wiegering A
Int J Colorectal Dis; 2021 May; 36(5):911-918. PubMed ID: 33078202
[TBL] [Abstract][Full Text] [Related]
14. The role of CIP2A in oral squamous cell carcinoma.
Basile JR; Czerninski R
Cancer Biol Ther; 2010 Oct; 10(7):700-2. PubMed ID: 20729627
[No Abstract] [Full Text] [Related]
15. MicroRNA-216a inhibits the growth and metastasis of oral squamous cell carcinoma by targeting eukaryotic translation initiation factor 4B.
Li L; Ma HQ
Mol Med Rep; 2015 Aug; 12(2):3156-62. PubMed ID: 25955794
[TBL] [Abstract][Full Text] [Related]
16. CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
Tian Y; Chen H; Qiao L; Zhang W; Zheng J; Zhao W; Chen JJ; Zhang W
J Cell Mol Med; 2018 Sep; 22(9):4150-4160. PubMed ID: 29893470
[TBL] [Abstract][Full Text] [Related]
17. miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes.
Hung PS; Liu CJ; Chou CS; Kao SY; Yang CC; Chang KW; Chiu TH; Lin SC
PLoS One; 2013; 8(11):e79926. PubMed ID: 24302991
[TBL] [Abstract][Full Text] [Related]
18. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
[TBL] [Abstract][Full Text] [Related]
19. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 May; 36(5):3583-9. PubMed ID: 25560487
[TBL] [Abstract][Full Text] [Related]
20. miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer.
Libório-Kimura TN; Jung HM; Chan EK
Oral Oncol; 2015 Feb; 51(2):151-7. PubMed ID: 25500095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
